The Third Failed Trial of Void, and Whether the Drug Ever Got a Fair Chance
A man too fragile for surgery has failed three trials of void. Before anyone accepts catheter dependence, the question is whether his medical therapy has actually run its full course — or whether the clock on it never really started.
A.G., 79, lost his wife of fifty-one years eight months ago and now lives with his daughter's family, an arrangement everyone describes as working well except for the one thing that keeps landing him back in the emergency department. He had a myocardial infarction five months ago, is on dual antiplatelet therapy, and his cardiology team has been direct that any elective surgery carries meaningfully elevated risk right now. Four months ago he had his first episode of acute urinary retention, was catheterized, and started on tamsulosin and dutasteride together at that time. A trial of void one week later failed. A second attempt three weeks after that also failed. He is now three weeks out from a third failed trial of void and currently catheter-dependent, with today's visit meant to decide what happens next. Before any of this began he had been remarkably independent for his age — driving himself to church twice a week, doing his own grocery shopping — and the catheter has been, in his own words, "the first thing that's made me feel like an old man."
His prostate is moderately enlarged, around 45mL, and his flow studies before the first retention episode showed reduced peak flow consistent with obstruction, not an obviously weak detrusor contraction — though no formal pressure-flow urodynamic study has ever actually been done, a gap that matters more than it might in a straightforward case, since it means every decision since his first retention has rested on an assumption about the mechanism rather than a confirmed one. He has tolerated the medications without side effects. The dutasteride, notably, has been running for only four months — well short of the two-year time course over which the drug's own pivotal trials measured gland-volume reduction, a detail easy to lose track of across three separate retention episodes and three separate emergency department visits, each of which understandably focused on the acute problem in front of it rather than the medication timeline running quietly in the background. Nobody documented the dutasteride start date consistently across those three visits; reconstructing it required pulling the original discharge summary from four months ago, the only place the actual date had been recorded at all.
Whether three failures mean the same thing they look like
Three failed trials of void on maximal medical therapy is a reasonable ceiling in a patient this fragile. ALFAUR, the largest randomized trial of a trial without catheter after acute retention, got roughly 62% of men voiding successfully on alfuzosin against 48% on placebo — and those were first episodes, not third attempts. Each catheter removal and reinsertion carries its own infection and trauma risk, and a fourth attempt offers diminishing odds. I'd move to planned intermittent catheterization or an indwelling catheter rather than put him through a fourth cycle.
Before we call this maximal medical therapy, I'd look at the actual timeline. Dutasteride has been running only four months. The pooled dutasteride phase III program — ARIA 3001, 3002 and 3003, Roehrborn and colleagues — ran its patients a full 24 months and saw gland volume still coming down across that period; four months is early on that curve, not the end of it. Calling three trials of void in his first four months a fair test of the drug isn't quite accurate; the drug hasn't finished acting yet. Conceding catheter dependence now may be premature.
I take the morbidity point seriously — I'm not proposing more failed attempts for their own sake, only that "maximal therapy" needs the drug's own timeline to actually elapse before we can call the therapy itself maximal.
You're both arguing about how long to wait on the same assumption — that this is an obstruction problem the drugs simply haven't fully treated yet. Nobody has actually confirmed that with pressure-flow urodynamics. Three failed trials of void are equally consistent with a detrusor that's begun to fail, which no amount of tamsulosin or dutasteride will ever fix. Get the study before committing to either path — it tells us whether more time on the drug is worth trying at all, or whether we've been treating the wrong problem from the start.
Agreed: obtain a formal pressure-flow urodynamic study before attempting another trial of void. If it confirms obstruction with preserved detrusor contractility, one further trial of void is reasonable once dutasteride has been running eight to nine months (still early against its trial time course, but far enough along to be a fairer test than four). If it shows detrusor failure, the plan moves to indwelling catheter or clean intermittent catheterization and no further trials of void are attempted.
Not agreed: if the urodynamic findings are mixed or ambiguous, whether that still counts as grounds for one more attempt or whether three real-world failures should already be treated as sufficient evidence regardless of what the study shows. Left open pending the actual result.